For archived live coverage of the hearing of the FDA’s advisory panel, click here.
By a narrow margin, an independent panel of advisers to the Food and Drug Administration on Wednesday decided that data from a single trial of an experimental drug developed by Amylyx Pharmaceuticals were not sufficient to conclude the therapy was an effective treatment against ALS.
Create a display name to comment
This name will appear with your comment
